Skip to main content
. 2021 May 31;22(11):5908. doi: 10.3390/ijms22115908

Figure 8.

Figure 8

Treatment with the CXCR7 agonist TC14012 attenuated hypertrophic remodeling and activated pERK signaling in SM-CXCL12−/− mice. (A) Experimental scheme studying the effects of the CXCR7 agonist TC14012 in SM-CXCL12−/− mice. (B–E) Bar graphs representing the echocardiographic parameters (B) interventricular septum diameter (IVSD), (C) left ventricular posterior wall diameter (LVPWD), (D) ejection fraction (EF), and (E) fractional shortening (FS), n = 10 per group. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 from one-way ANOVA followed by Tukey’s multiple comparisons test. (F) Western blot analyses of CXCR4, CXCR7, and GAPDH, phosphorylated and total protein levels of AKT, ERK1/2, and RhoA in heart lysates of controls, SM-CXCL12−/−, and cKO + TC14012 mice. (G–K) Bar graphs displaying the quantification of CXCR4, CXCR7 expression, and phosphorylated protein levels of AKT, ERK1/2, and RhoA, n = 3, ** p < 0.01, *** p < 0.001, **** p < 0.0001 from one-way ANOVA followed by Tukey’s multiple comparisons test. Data represent mean ± SD.